tradingkey.logo

Mereo BioPharma Group PLC

MREO
1.960USD
-0.040-2.00%
Cierre 10/14, 16:00ETCotizaciones retrasadas 15 min
1.56BCap. mercado
PérdidaP/E TTM

Mereo BioPharma Group PLC

1.960
-0.040-2.00%

Más Datos de Mereo BioPharma Group PLC Compañía

Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.

Información de Mereo BioPharma Group PLC

Símbolo de cotizaciónMREO
Nombre de la empresaMereo BioPharma Group PLC
Fecha de salida a bolsaJun 09, 2016
Director ejecutivoDr. Denise V. Scots-Knight, Ph.D.
Número de empleados36
Tipo de seguridadDepository Receipt
Fin del año fiscalJun 09
DirecciónOne Cavendish Place
CiudadLONDON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited Kingdom
Código postalW1G0QF
Teléfono443330237300
Sitio Webhttps://www.mereobiopharma.com/
Símbolo de cotizaciónMREO
Fecha de salida a bolsaJun 09, 2016
Director ejecutivoDr. Denise V. Scots-Knight, Ph.D.

Ejecutivos de Mereo BioPharma Group PLC

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Alexandra (Wills) Hughes-Wilson
Ms. Alexandra (Wills) Hughes-Wilson
Chief Patient Access and Commercial Planning
Chief Patient Access and Commercial Planning
94.77K
+174.32%
Dr. John A. Lewicki, Ph.D.
Dr. John A. Lewicki, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
78.63K
+61.20%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
25.05K
--
Dr. Jeremy Bender, Ph.D.
Dr. Jeremy Bender, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
12.55K
--
Dr. Deepika R. Pakianathan, Ph.D.
Dr. Deepika R. Pakianathan, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Justin Roberts
Mr. Justin Roberts
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Charles E. Sermon
Mr. Charles E. Sermon
General Counsel and Business Development, Company Secretary
General Counsel and Business Development, Company Secretary
--
--
Dr. Anders Ekblom, M.D., Ph.D.
Dr. Anders Ekblom, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Christine Fox
Ms. Christine Fox
Chief Financial Officer
Chief Financial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Alexandra (Wills) Hughes-Wilson
Ms. Alexandra (Wills) Hughes-Wilson
Chief Patient Access and Commercial Planning
Chief Patient Access and Commercial Planning
94.77K
+174.32%
Dr. John A. Lewicki, Ph.D.
Dr. John A. Lewicki, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
78.63K
+61.20%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
25.05K
--
Dr. Jeremy Bender, Ph.D.
Dr. Jeremy Bender, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
12.55K
--
Dr. Deepika R. Pakianathan, Ph.D.
Dr. Deepika R. Pakianathan, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Justin Roberts
Mr. Justin Roberts
Non-Executive Independent Director
Non-Executive Independent Director
--
--

Desglose de ingresos

Sin datos
Sin datos
Por negocio
Por región
Sin datos

Estadísticas de accionistas

Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Janus Henderson Investors
11.12%
Rubric Capital Management LP
9.62%
Northpond Ventures, LLC
6.85%
Frazier Life Sciences Management, L.P.
5.93%
Mangrove Partners
5.43%
Otro
61.04%
Accionistas
Accionistas
Proporción
Janus Henderson Investors
11.12%
Rubric Capital Management LP
9.62%
Northpond Ventures, LLC
6.85%
Frazier Life Sciences Management, L.P.
5.93%
Mangrove Partners
5.43%
Otro
61.04%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
31.41%
Investment Advisor/Hedge Fund
17.15%
Venture Capital
6.90%
Private Equity
5.93%
Investment Advisor
4.34%
Research Firm
3.16%
Individual Investor
0.86%
Bank and Trust
0.12%
Otro
30.12%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
168
109.81M
69.02%
-7.57M
2025Q2
167
124.56M
78.34%
-3.58M
2025Q1
176
112.84M
70.99%
-23.15M
2024Q4
174
116.69M
75.21%
-16.90M
2024Q3
167
107.29M
69.42%
-17.56M
2024Q2
164
101.82M
66.22%
-5.20M
2024Q1
162
84.96M
60.56%
-41.79M
2023Q4
143
78.69M
56.11%
-37.03M
2023Q3
141
72.18M
51.57%
-33.53M
2023Q2
149
64.87M
50.46%
-34.19M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Janus Henderson Investors
17.69M
11.12%
-5.05M
-22.20%
Jun 30, 2025
Rubric Capital Management LP
15.31M
9.62%
--
--
Jun 30, 2025
Northpond Ventures, LLC
10.90M
6.85%
+10.90M
--
Jun 04, 2025
Frazier Life Sciences Management, L.P.
9.44M
5.93%
+1.37M
+16.98%
Jun 30, 2025
Mangrove Partners
8.64M
5.43%
--
--
Jun 30, 2025
Deerfield Management Company, L.P.
6.71M
4.22%
--
--
Jun 30, 2025
Alkeon Capital Management LLC
4.70M
2.95%
--
--
Jun 30, 2025
Rock Springs Capital Management LP
4.47M
2.81%
-2.22M
-33.20%
Jun 30, 2025
683 Capital Management LLC
4.35M
2.73%
-285.00K
-6.15%
Jun 30, 2025
Clearline Capital LP
3.62M
2.27%
+400.27K
+12.44%
Jun 30, 2025
Ver más

ETFs relacionados

Actualizado: lun., 6 de oct
Actualizado: lun., 6 de oct
Nombre
Proporción
iShares Genomics Immunology and Healthcare ETF
0.56%
Virtus LifeSci Biotech Clinical Trials ETF
0.48%
SPDR S&P International Small Cap ETF
0.02%
ActivePassive International Equity ETF
0.01%
Tema Heart & Health ETF
0%
Tema Oncology ETF
0%
Formidable ETF
0%
iShares Genomics Immunology and Healthcare ETF
Proporción0.56%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.48%
SPDR S&P International Small Cap ETF
Proporción0.02%
ActivePassive International Equity ETF
Proporción0.01%
Tema Heart & Health ETF
Proporción0%
Tema Oncology ETF
Proporción0%
Formidable ETF
Proporción0%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI